John Bentivoglio represents pharmaceutical, medical device and biotechnology manufacturers in criminal, civil and administrative enforcement actions by the U.S. Department of Justice, state attorneys general and other agencies.


Mr. Bentivoglio has negotiated successful resolutions of such matters for Allergan, Calloway Laboratories, Jazz Pharmaceuticals, Merck & Co., Otsuka Pharmaceuticals and Serono, among others. He also has counseled more than a dozen companies on the negotiation and implementation of Corporate Integrity Agreements. In addition to assisting companies in enforcement actions, he regularly advises clients on compliance program issues and on federal and state anti-kickback and false claims statutes, FDA advertising and promotional rules, and Medicare and Medicaid regulatory issues. 

From 1997-2000, he served as associate deputy attorney general and special counsel for health care fraud at the DOJ, where he advised the attorney general and deputy attorney general on national enforcement initiatives, health care investigation and prosecution policies, and interagency coordination. From 1996-1997, he was a special assistant to the assistant attorney general, Criminal Division. Earlier in his career, Mr. Bentivoglio served as a professional staff member to Sen. Joseph R. Biden Jr., chairman, Committee on the Judiciary.

Mr. Bentivoglio repeatedly has been selected for inclusion in Chambers USA: America’s Leading Lawyers for Business and The Best Lawyers in America, and was recognized as a 2018 “BTI Client Service All-Star” by The BTI Consulting Group. He also was selected for inclusion in Who’s Who Legal: Life Sciences, named a Non-IP Litigation Star in LMG Life Sciences 2016 and a Life Sciences Star in LMG Life Sciences 2018.

Mr. Bentivoglio serves on the board of directors of the Children’s Law Center in Washington, D.C. He also is an active volunteer firefighter and EMT with the Bethesda-Chevy Chase Rescue Squad in Bethesda, Maryland.



  • "DOJ and OIG Enforcement Update," Pharmaceutical Compliance Forum, Philadelphia (March, September 2016);
  • 17th Annual Pharmaceutical and Medical Device Compliance Congress, Washington, D.C. (October 2016);
  • "AUSA Roundtable: Hot Topics in DOJ Enforcement in the Pharmaceutical Industry" (Moderator), Pharmaceutical Compliance Forum, Washington, D.C. (November 2014-2016);
  • "DOJ and OIG Enforcement Update," Pharmaceutical Compliance Forum, Philadelphia (September 2013);
  • "Key Trends in Pharmaceutical & Medical Device Corporate Integrity Agreements," The Intersecting Worlds of Drug, Device, Biologics and Health Law (FDLI/AHLA Seminar), Washington, D.C. (May 2012);
  • "Trends in Pharmaceutical Corporate Integrity Agreements (CIAs): Evolution in Recent CIAs and Likely Future Provisions," Pharmaceutical Compliance Forum, Cary, N.C. (March 2012);
  • "Whistleblower Provisions of Dodd-Frank: Implications for Global Pharma Compliance Programs," Asian Pharmaceutical Compliance Congress, Singapore (September 2011);
  • "Roundtable on Practical Approaches to Anti-Bribery/Anti-Corruption Programs," International Pharmaceutical Compliance Congress, Istanbul (May 2011);
  • "Hot Topics in Biopharmaceutical Compliance" (Moderator), PhRMA Law Section Meeting, Wilmington, Del. (April 2011);
  • "Attorney-Client Privilege in the Context of Compliance Work," AdvaMed Drug and Diagnostic Compliance Group Meeting, Irvine, Calif. (April 2011);
  • "Negotiating a Corporate Integrity Agreement: Lessons Learned — and How to Use These Lessons to Strengthen Your Compliance Program," Pharmaceutical Compliance Forum, Cary, N.C. (March 2011);
  • "State Attorney General Investigations of Pharmaceutical Manufacturers," Pharmaceutical Compliance Congress, Washington, D.C. (October 2011);
  • "Health Care Fraud & Abuse: Responding to Emerging Risk Areas," BNA Audio conference (March 2010);
  • "Pharmaceutical and Medical Device Transparency & Disclosure Laws and Initiatives," Pharmaceutical Compliance Forum, Cary, N.C. (March 2010); and
  • "How Transparency Will Impact Government Enforcement and Private Litigation," National Disclosure Summit for Drug, Device and Biotech Manufacturers, Washington, D.C. (March 2010).



  • J.D., Georgetown University Law Center
  • B.A., University of California, Berkeley


  • District of Columbia
  • Maryland

Government Service

  • U.S. Department of Justice: Associate Deputy Attorney General (1998-2000); Counsel to the Deputy Attorney General & Special Counsel for Health Care Fraud (1997-1998); Trial Attorney, Criminal Division (1996-1997)
  • Committee on the Judiciary, U.S. Senate: Professional Staff Member (1988-1992); Legislative Assistant (1986-1988)

John T. Bentivoglio

Partner, Health Care and Life Sciences